Predictors of outcome in routine care for Cryptococcal meningitis in Western Kenya: lessons for HIV outpatient care in resource-limited settings

Postgrad Med J. 2013 Feb;89(1048):73-7. doi: 10.1136/postgradmedj-2012-130823. Epub 2012 Oct 30.

Abstract

Purpose: Cryptococcal meningitis is a leading cause of mortality among HIV-infected individuals in sub-Saharan Africa but little is known about its treatment and outcomes in decentralised HIV outpatient settings. We assessed adherence to treatment guidelines and determined predictors of survival.

Design: A computerised laboratory database identified HIV-infected adults with cryptococcal meningitis at Family AIDS Care and Education Services in Nyanza Province, Kenya, between 2005-2009. Medical records were reviewed. Kaplan-Meier survival curves were generated. Bivariate and multivariate Cox proportional hazards models were used to determine associations between key clinical characteristics and survival.

Results: Medical records were located for 79% (71/90). Mortality was 38% (27/71) over a median follow-up period of 201 days (IQR: 10-705 days). Adherence to local guidelines for treatment of cryptococcal meningitis was 48% (34/71). Higher body mass index was associated with improved survival (HR: 0.82, 95% CI (0.68 to 0.99)) even after controlling for factors such as age, CD4 cell count, receipt of highly active anti-retroviral therapy, and treatment with any anti-fungal therapy.

Conclusions: Cryptococcal meningitis diagnosed in routine HIV outpatient settings is largely treated as an outpatient and adherence to treatment guidelines is poor. Body mass index is a critical independent predictor of outcome. Additional research to determine the most effective strategies to reduce premature mortality is urgently needed.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS-Related Opportunistic Infections / complications*
  • AIDS-Related Opportunistic Infections / drug therapy
  • AIDS-Related Opportunistic Infections / mortality
  • Adult
  • Age Factors
  • Ambulatory Care
  • Antifungal Agents / therapeutic use*
  • Antiretroviral Therapy, Highly Active / methods*
  • Body Mass Index
  • CD4 Lymphocyte Count
  • Guideline Adherence
  • HIV Infections / complications*
  • HIV Infections / drug therapy
  • HIV Infections / mortality
  • Humans
  • Kenya
  • Meningitis, Cryptococcal / drug therapy*
  • Meningitis, Cryptococcal / etiology
  • Meningitis, Cryptococcal / mortality
  • Practice Guidelines as Topic
  • Proportional Hazards Models
  • Treatment Outcome

Substances

  • Antifungal Agents